Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies
John Cooper, Parth Patel, Joven Tristeza, Alexander Yang
TL;DR
This review explores the molecular causes and treatment options for metabolic-associated steatotic liver disease, a major global health issue.
Contribution
The paper provides a comprehensive overview of molecular mechanisms and clinical trials for MASLD.
Findings
MASLD is the leading reason for liver transplants globally.
Few effective pharmacological treatments for MASLD are currently available.
The paper summarizes past, current, and future clinical trials for MASLD therapies.
Abstract
Metabolic-associated steatotic liver disease (MASLD) is a burgeoning worldwide burden and is currently the leading indication for a liver transplant. Despite the growing burden of disease, there are few pharmacological treatments available. The underlying molecular mechanisms of the development of MASLD are still being elucidated. In this review, we will summarize the known molecular mechanisms in the development of MASLD along with past, current, and future pharmacologic clinical trials.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLiver Disease Diagnosis and Treatment · Pancreatic function and diabetes · Diet, Metabolism, and Disease